辉瑞公司Pfizer Inc.（PFE）2024年第一季度收益电话会议演示报告「NYSE」（英文版）（16页）.pdf

《辉瑞公司Pfizer Inc.（PFE）2024年第一季度收益电话会议演示报告「NYSE」（英文版）（16页）.pdf》由会员分享，可在线阅读，更多相关《辉瑞公司Pfizer Inc.（PFE）2024年第一季度收益电话会议演示报告「NYSE」（英文版）（16页）.pdf（16页珍藏版）》请在三个皮匠报告上搜索。

1、Breakthroughs that change patients lives May 1,2024First Quarter 2024 Earnings TeleconferenceIntroductionFrancesca DeMartinoChief Investor Relations Officer,Senior Vice President3First Quarter 2024 EarningsForward-Looking Statements and Non-GAAP Financial Informationl Our discussions during this con

2、ference call will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.We include forward-looking statements about,among other topics,our anticipated operatin

3、g and financial performance,including financial guidance and projections;changes to Pfizers commercial organization;reorganizations;business plans,strategy,goals and prospects;our Environmental,Social and Governance(ESG)priorities,strategy and goals;expectations for our product pipeline,in-line prod

4、ucts and product candidates,including anticipated regulatory submissions,data read-outs,study starts,approvals,launches,clinical trial results and other developing data,revenue contribution and projections,potential pricing and reimbursement,potential market dynamics,size and utilization rates,growt

5、h,performance,timing of exclusivity and potential benefits;strategic reviews,capital allocation objectives,an enterprise-wide cost realignment program(including anticipated costs,savings and potential benefits),dividends and share repurchases;plans for and prospects of our acquisitions,dispositions

6、and other business development activities,including our December 2023 acquisition of Seagen,and our ability to successfully capitalize on these opportunities;manufacturing and product supply;our ongoing efforts to respond to COVID-19,including our COVID-19 products and our expectations regarding the